产品
编 号：F114175
分子式：C19H20N2O3
分子量：324.37
分子式：C19H20N2O3
分子量：324.37
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
663
In-stock
1mg
422
In-stock
5mg
930
In-stock
10mg
1450
In-stock
50mg
4130
In-stock
100mg
5890
In-stock
结构图
CAS No: 130641-38-2
产品详情
生物活性：
Bindarit (AF2838) is a selective inhibitor of the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8, and no effect on other CC and CXC chemokines such as MIP-1α/CCL3, MIP-1β/CCL4, MIP-3/CCL23. Bindarit also has anti-inflammatory activity.
体内研究：
Bindarit (50 mg/kg；口服给药；每天；持续 4 个月、6 个月、8 个月；NZB/W F1 雌性小鼠) 延迟蛋白尿的发生并显著防止肾功能损害。Bindarit 完全阻止单核细胞趋化蛋白 (MCP-1) 上调。Animal Model:NZB/W F1 female mice ( two months of age)
Dosage:50 mg/kg
Administration:Oral administration; every day; for 4 months, 6 months, 8 months
Result:Delayed the onset of proteinuria and significantly protected from renal function impairment.
体外研究：
Bindarit (10-300 μM；48 小时) 在 100 μM 和 300 μM 时分别显著抑制血小板衍生生长因子-BB (PDGF-BB) 诱导的大鼠 VSMC 增殖 27% 和 42%。
Bindarit (AF2838) is a selective inhibitor of the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8, and no effect on other CC and CXC chemokines such as MIP-1α/CCL3, MIP-1β/CCL4, MIP-3/CCL23. Bindarit also has anti-inflammatory activity.
体内研究：
Bindarit (50 mg/kg；口服给药；每天；持续 4 个月、6 个月、8 个月；NZB/W F1 雌性小鼠) 延迟蛋白尿的发生并显著防止肾功能损害。Bindarit 完全阻止单核细胞趋化蛋白 (MCP-1) 上调。Animal Model:NZB/W F1 female mice ( two months of age)
Dosage:50 mg/kg
Administration:Oral administration; every day; for 4 months, 6 months, 8 months
Result:Delayed the onset of proteinuria and significantly protected from renal function impairment.
体外研究：
Bindarit (10-300 μM；48 小时) 在 100 μM 和 300 μM 时分别显著抑制血小板衍生生长因子-BB (PDGF-BB) 诱导的大鼠 VSMC 增殖 27% 和 42%。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备